Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Rhea-AI Summary

Processa Pharmaceuticals (Nasdaq: PCSA) has announced its participation in two major conferences this September. The company will attend the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York. Management will conduct one-on-one investor meetings and deliver a company presentation, which will be available on-demand from September 9th at 7:00 am Eastern time on Processa's website.

Additionally, Processa will participate in the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona from September 13-17, 2024. During this event, management will meet with clinicians, researchers, industry key opinion leaders, and potential partners. These conferences provide Processa with valuable opportunities to showcase their developments and network within the pharmaceutical and investment communities.

HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences during the month of September:

• H.C. Wainwright 26^th Annual Global Investment Conference, September 9-11, 2024, at the Lotte New York Palace Hotel. Management will be holding one-on-one meetings with investors and will deliver a company presentation. The recorded presentation will be available on demand beginning Monday, September 9^th at 7:00am Eastern time on the Investors section of Processa’s website and here.
• European Society for Medical Oncology (ESMO) Congress 2024, September 13-17, 2024, in Barcelona. Management will be holding meetings with clinicians, researchers, industry key opinion leaders and potential partners.

About Processa Pharmaceuticals, Inc.

Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.

For more information, visit our website at www.processapharma.com.

Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com

Investor Relations Contact:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
ybriggs@lhai.com

# # #

FAQ

Which conferences will Processa Pharmaceuticals (PCSA) attend in September 2024?

Processa Pharmaceuticals (PCSA) will attend the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York, and the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024, in Barcelona.

When and where will Processa Pharmaceuticals' (PCSA) company presentation be available for the H.C. Wainwright conference?

Processa Pharmaceuticals' (PCSA) company presentation for the H.C. Wainwright conference will be available on-demand beginning Monday, September 9th, 2024, at 7:00 am Eastern time on the Investors section of Processa's website.

What activities will Processa Pharmaceuticals (PCSA) engage in during the ESMO Congress 2024?

During the ESMO Congress 2024, Processa Pharmaceuticals (PCSA) management will hold meetings with clinicians, researchers, industry key opinion leaders, and potential partners.

Where is the H.C. Wainwright 26th Annual Global Investment Conference being held?

The H.C. Wainwright 26th Annual Global Investment Conference is being held at the Lotte New York Palace Hotel from September 9-11, 2024.